Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 6-Oct 4:02 PM ET)
Immunome (IMNM) Gets a Hold from Stifel Nicolaus
TipRanks (Tue, 6-Oct 6:58 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)
TipRanks (Mon, 5-Oct 12:50 PM ET)
Immunome Restructures BMS Deal, Gains Key Patent Rights
TipRanks (Mon, 5-Oct 9:05 AM ET)
Business Wire (Wed, 30-Sep 7:45 AM ET)
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire (Wed, 2-Sep 7:45 AM ET)
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 11-Aug 4:02 PM ET)
Business Wire (Mon, 20-Jul 7:30 AM ET)
Business Wire (Wed, 8-Jul 7:30 AM ET)
Immunome's $400 Million Public Offering Draws Focus to Cancer Therapy Pipeline and Investor Demand
Market Chameleon (Wed, 17-Dec 2:55 AM ET)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of October 7, 2026, IMNM stock price declined to $19.09 with 1,036,021 million shares trading.
IMNM has a beta of 1.27, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.09 to the broad based SPY ETF.
IMNM has a market cap of $2.25 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.65 earnings per share. This fell short of revenue expectation by $-533,336 and missed earnings estimates by -$.14.
In the last 3 years, IMNM traded as high as $30.96 and as low as $5.15.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
IMNM has outperformed the market in the last year with a return of +32.5%, while the SPY ETF gained +16.9%. However, in the most recent history, IMNM shares have underperformed the stock market with its stock returning -20.1% in the last 3 month period and -25.8% for the last 2 week period, while SPY has returned +3.7% and +0.5%, respectively.
IMNM support price is $18.57 and resistance is $20.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.
